Vir Biotechnology, Inc. VIR
We take great care to ensure that the data presented and summarized in this overview for Vir Biotechnology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIR
View all-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$116 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$91.3 Million0.0% of portfolio
-
State Street Corp Boston, MA5.07MShares$35.3 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.22MShares$22.4 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$15.3 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.92MShares$13.3 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY1.81MShares$12.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.72MShares$11.9 Million0.01% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.56MShares$10.8 Million26.84% of portfolio
Latest Institutional Activity in VIR
Top Purchases
Top Sells
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Insider Transactions at VIR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2025
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,373
-8.49%
|
$66,357
$9.14 P/Share
|
|
Feb 24
2025
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,056
-1.42%
|
$90,504
$9.45 P/Share
|
|
Feb 24
2025
|
Ann M. Hanly EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
14,168
-10.73%
|
$127,512
$9.45 P/Share
|
|
Feb 24
2025
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
5,140
-5.59%
|
$46,260
$9.45 P/Share
|
|
Feb 24
2025
|
Marianne De Backer Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,122
-1.86%
|
$145,098
$9.45 P/Share
|
|
Feb 24
2025
|
Brent Sabatini SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,562
-3.24%
|
$14,058
$9.45 P/Share
|
|
Feb 22
2025
|
Jason O'Byrne EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.81%
|
-
|
|
Feb 22
2025
|
Vanina De Verneuil EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+27.56%
|
-
|
|
Feb 22
2025
|
Marianne De Backer Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+21.71%
|
-
|
|
Feb 22
2025
|
Brent Sabatini SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+29.33%
|
-
|
|
Feb 22
2025
|
Mark Eisner EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.81%
|
-
|
|
Feb 18
2025
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,964
-1.52%
|
$98,676
$9.81 P/Share
|
|
Feb 13
2025
|
Brent Sabatini SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,562
-5.25%
|
$14,058
$9.15 P/Share
|
|
Jan 08
2025
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
10,960
-0.83%
|
$131,520
$12.52 P/Share
|
|
Dec 02
2024
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
76
-0.13%
|
$608
$8.22 P/Share
|
|
Nov 15
2024
|
Jason O'Byrne EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Nov 06
2024
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
4,397
-7.16%
|
$43,970
$10.11 P/Share
|
|
Nov 05
2024
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,347
-3.68%
|
$21,123
$9.47 P/Share
|
|
Nov 01
2024
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
1,403
-2.15%
|
$9,821
$7.2 P/Share
|
|
Oct 23
2024
|
George A Scangos Director |
SELL
Other acquisition or disposition
|
Indirect |
1,196,540
-34.19%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 621K shares |
|---|---|
| Other acquisition or disposition | 1.25M shares |
| Open market or private sale | 184K shares |
|---|---|
| Other acquisition or disposition | 1.25M shares |